The Europe Pruritus Therapeutics Market should witness market growth of 4.1% CAGR during the forecast period (2023-2030).
For severe and ongoing pruritus, systemic medication such as antihistamines, antidepressants, immunosuppressants, and opioid antagonists are administered. These drugs either affect the central nervous system's itch pathway or the underlying cause of pruritus. Light therapy, or phototherapy, uses ultraviolet (UV) light to treat pruritus caused by skin conditions such as psoriasis and irritation. The skin's condition improves with UV light, which helps suppress inflammation and ease itching. Modifying one's lifestyle, avoiding triggers, maintaining proper skin hygiene, utilizing gentle skincare products, and managing anxiety can complement pharmacological treatments and alleviate pruritus.
One of the emerging market trends is the use of cutting-edge technology in creating products to treat fungal infections, including pruritus. This method allows for the use of typically unsoluble medications, increasing the drug's bioavailability and effectiveness in tablet form. Thus, developing and distributing pharmaceuticals using innovative technology helps increase their efficacy, thereby improving therapy alternatives. These technological developments will encourage the market to grow favorably. The market is progressing due to regulatory agencies' increased special designation. Additionally, the market will benefit from profitable growth prospects due to the rise in demand for over-the-counter topical corticosteroids.
The U.K. government's "Future of an Aging Population" study estimates that by 2040, one in seven citizens will be over 75. By 2037, 1.42 million more families, or an increase of 161% over 25 years, are expected to be headed by an individual who is 85 years or older. Over 5.5 million more people are anticipated to contribute to the percentage of working-age people over 50 and at the state pension age (SPA), which is predicted to increase from 26% in 2012 to 34% in 2050. Due to aging-related skin changes and a higher prevalence of specific underlying disorders, elderly people are more likely to experience pruritus. Because of this, the regional market will expand due to the aging population.
The Germany market dominated the Europe Pruritus Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $751.4 million by 2030. The UK market is anticipated to grow at a CAGR of 3.3% during (2023-2030). Additionally, The France market would exhibit a CAGR of 4.9% during (2023-2030).
Based on Disease Type, the market is segmented into Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria and Others. Based on Product, the market is segmented into Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressant, Calcineurin Inhibitors and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bristol Myers Squibb Company, Novartis AG, Pfizer, Inc., Sanofi S.A., Astellas Pharma, Inc., Cara Therapeutics, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceuticals Industries Ltd., Amgen, Inc., and AbbVie, Inc.
For severe and ongoing pruritus, systemic medication such as antihistamines, antidepressants, immunosuppressants, and opioid antagonists are administered. These drugs either affect the central nervous system's itch pathway or the underlying cause of pruritus. Light therapy, or phototherapy, uses ultraviolet (UV) light to treat pruritus caused by skin conditions such as psoriasis and irritation. The skin's condition improves with UV light, which helps suppress inflammation and ease itching. Modifying one's lifestyle, avoiding triggers, maintaining proper skin hygiene, utilizing gentle skincare products, and managing anxiety can complement pharmacological treatments and alleviate pruritus.
One of the emerging market trends is the use of cutting-edge technology in creating products to treat fungal infections, including pruritus. This method allows for the use of typically unsoluble medications, increasing the drug's bioavailability and effectiveness in tablet form. Thus, developing and distributing pharmaceuticals using innovative technology helps increase their efficacy, thereby improving therapy alternatives. These technological developments will encourage the market to grow favorably. The market is progressing due to regulatory agencies' increased special designation. Additionally, the market will benefit from profitable growth prospects due to the rise in demand for over-the-counter topical corticosteroids.
The U.K. government's "Future of an Aging Population" study estimates that by 2040, one in seven citizens will be over 75. By 2037, 1.42 million more families, or an increase of 161% over 25 years, are expected to be headed by an individual who is 85 years or older. Over 5.5 million more people are anticipated to contribute to the percentage of working-age people over 50 and at the state pension age (SPA), which is predicted to increase from 26% in 2012 to 34% in 2050. Due to aging-related skin changes and a higher prevalence of specific underlying disorders, elderly people are more likely to experience pruritus. Because of this, the regional market will expand due to the aging population.
The Germany market dominated the Europe Pruritus Therapeutics Market by Country in 2022, and would continue to be a dominant market till 2030; thereby, achieving a market value of $751.4 million by 2030. The UK market is anticipated to grow at a CAGR of 3.3% during (2023-2030). Additionally, The France market would exhibit a CAGR of 4.9% during (2023-2030).
Based on Disease Type, the market is segmented into Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria and Others. Based on Product, the market is segmented into Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressant, Calcineurin Inhibitors and Others. Based on Distribution Channel, the market is segmented into Drug Stores & Retail Pharmacies, Hospital Pharmacies and Online Providers. Based on countries, the market is segmented into Germany, UK, France, Russia, Spain, Italy, and Rest of Europe.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Bristol Myers Squibb Company, Novartis AG, Pfizer, Inc., Sanofi S.A., Astellas Pharma, Inc., Cara Therapeutics, Inc., GlaxoSmithKline PLC (GSK), Teva Pharmaceuticals Industries Ltd., Amgen, Inc., and AbbVie, Inc.
Scope of the Study
By Disease Type
- Atopic Dermatitis
- Allergic Contact Dermatitis
- Urticaria
- Others
By Product
- Corticosteroids
- Antihistamines
- Local Anesthetics
- Counterirritants
- Immunosuppressant
- Calcineurin Inhibitors
- Others
By Distribution Channel
- Drug Stores & Retail Pharmacies
- Hospital Pharmacies
- Online Providers
By Country
- Germany
- UK
- France
- Russia
- Spain
- Italy
- Rest of Europe
Key Market Players
List of Companies Profiled in the Report:
- Bristol Myers Squibb Company
- Novartis AG
- Pfizer, Inc.
- Sanofi S.A.
- Astellas Pharma, Inc.
- Cara Therapeutics, Inc.
- GlaxoSmithKline PLC (GSK)
- Teva Pharmaceuticals Industries Ltd.
- Amgen, Inc.
- AbbVie, Inc.
Unique Offerings
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market at a Glance
Chapter 3. Market Overview
Chapter 4. Europe Pruritus Therapeutics Market by Disease Type
Chapter 5. Europe Pruritus Therapeutics Market by Product
Chapter 6. Europe Pruritus Therapeutics Market by Distribution Channel
Chapter 7. Europe Pruritus Therapeutics Market by Country
Chapter 8. Company Profiles
Companies Mentioned
- Bristol Myers Squibb Company
- Novartis AG
- Pfizer, Inc.
- Sanofi S.A.
- Astellas Pharma, Inc.
- Cara Therapeutics, Inc.
- GlaxoSmithKline PLC (GSK)
- Teva Pharmaceuticals Industries Ltd.
- Amgen, Inc.
- AbbVie, Inc.
Methodology
LOADING...
